Application Value of 68 Ga-FAPI PET/CT in the Evaluation of Myelofibrotic Diseases.

Abstract

PURPOSE:

Fibroblast activation protein is highly expressed in neoplastic lesions and various fibrotic tissues, making it an attractive target for disease evaluation. 68 Ga-labeled fibroblast activation protein inhibitor (FAPI), a new tumor interstitial imaging agent, holds promise for evaluating myelofibrosis. Therefore, this study aimed to use 68 Ga-FAPI PET/CT for the noninvasive visualization and quantification of the extent of myelofibrosis.

PATIENTS AND METHODS:

This was a prospective clinical study involving 22 patients with myelofibrosis who underwent 68 Ga-FAPI PET/CT. The uptake of 68 Ga-FAPI was measured in their respective bone marrow and spleen, and the obtained imaging findings were compared with laboratory, cytogenetic, and histopathological data.

RESULTS:

68 Ga-FAPI uptake in the bone marrow was significantly and positively correlated with the myelofibrosis grade ( r > 0.8, P < 0.001). 68 Ga-FAPI PET/CT showed visually negative results in patients with grades 0-1 myelofibrosis and positive in those with grades 2-3, but the level of involvement varied. 68 Ga-FAPI PET/CT provides a noninvasive means of visualizing the extent of systemic bone marrow involvement and differentiation between the early and advanced stages of fibrosis.

CONCLUSIONS:

68 Ga-FAPI PET/CT shows promise as a method for visualizing and quantifying myelofibrosis, providing suitable sites for bone marrow biopsy. The extent of 68 Ga-FAPI uptake by bone marrow increases with the progression of myelofibrosis, thus it is a simple and noninvasive measurement that can be used to evaluate the progression of myelofibrosis. Nevertheless, although 68 Ga-FAPI PET/CT has demonstrated a potential value in prognostic assessment, further confirmation is needed.

• Authors: Ya Liu, Xue Li, Li Jing, Chunmei Guo, Zibei Wan, Feiyu Zhang, Pengqiang Wu, Zhanwen Huang
• Journal: Clinical nuclear medicine (Clin Nucl Med) Vol. 49 Issue 5 Pg. 404-408 (May 01 2024) ISSN: 1536-0229 [Electronic] United States
• PMID: 38465921 (Publication Type: Journal Article)
• Copyright: Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• Gallium-68
• Gallium Radioisotopes
• Fluorodeoxyglucose F18

Topics

• Humans
• Primary Myelofibrosis (diagnostic imaging)
• Positron Emission Tomography Computed Tomography
• Prospective Studies
• Biological Transport
• Gallium Radioisotopes
• Fluorodeoxyglucose F18